Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus

  • Read more about The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus

Opus Genetics, Inc.

By jpalfreyman on Fri, 02/28/2025 - 16:16
  • Read more about Opus Genetics, Inc.

Dissecting Human Immune Responses to Infection with Influenza or SARS-CoV-2

  • Read more about Dissecting Human Immune Responses to Infection with Influenza or SARS-CoV-2

The Effect of the Role Performance Strengthening Program on the Adaptive Performance and Competence of Nurses

  • Read more about The Effect of the Role Performance Strengthening Program on the Adaptive Performance and Competence of Nurses

Cognitive-Sensorimotor Function in Long-COVID

  • Read more about Cognitive-Sensorimotor Function in Long-COVID

COVID Feel Good-An Easy Self-Help Virtual Reality Protocol to Overcome the Psychological Burden of Coronavirus

  • Read more about COVID Feel Good-An Easy Self-Help Virtual Reality Protocol to Overcome the Psychological Burden of Coronavirus

EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL

  • Read more about EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL

NE3107 in Adults With Neurological Symptoms of Long COVID

  • Read more about NE3107 in Adults With Neurological Symptoms of Long COVID

Signet Therapeutics

By jpalfreyman on Wed, 02/26/2025 - 09:03
  • Read more about Signet Therapeutics

Elixirgen Therapeutics, Inc.

By jpalfreyman on Fri, 02/21/2025 - 10:49
  • Read more about Elixirgen Therapeutics, Inc.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • Current page 28
  • Page 29
  • Page 30
  • Page 31
  • Page 32
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA